iRhythm technologies CFO sells $254,630 in stock

Published 04/03/2025, 22:04
iRhythm technologies CFO sells $254,630 in stock

SAN FRANCISCO—Wilson Daniel G., Chief Financial Officer of iRhythm Technologies, Inc. (NASDAQ:IRTC), recently sold shares of the company’s common stock. According to a filing with the Securities and Exchange Commission, Mr. Wilson sold 2,341 shares on March 3 at a price of $108.77 per share, amounting to a total transaction value of $254,630. The transaction comes as the company’s stock has shown strong momentum, with a notable 58% gain over the past six months.

The sale was conducted to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units. Following this transaction, Mr. Wilson retains ownership of 45,307 shares in the company. According to InvestingPro data, analysts maintain a bullish outlook on IRTC, with price targets ranging from $104 to $152.

iRhythm Technologies, a leader in digital health care solutions, continues its operations from its headquarters in San Francisco, California. The company, currently valued at $3.37 billion, maintains strong liquidity with a healthy current ratio of 5.82 and has achieved impressive revenue growth of 20% in the latest period. For deeper insights into IRTC’s valuation and growth prospects, access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, iRhythm Technologies reported strong fourth-quarter results, surpassing Wall Street’s expectations with a 24% revenue increase to $164.3 million, beating the consensus estimate of $157.12 million. Earnings per share were $0.01, a significant improvement from the anticipated $0.35 loss per share. The company has projected its 2025 revenue to be between $675 and $685 million, aligning with analyst estimates. In light of these results, several analysts have adjusted their price targets for iRhythm, with Truist Securities, JPMorgan, and Needham raising their targets to $145, $145, and $138, respectively, while maintaining positive ratings. These adjustments reflect confidence in iRhythm’s growth trajectory, particularly in the U.S. market, and its ongoing international expansion efforts. The company is also making strides in regulatory remediation and plans to submit its MCT device to the FDA by the third quarter of 2025. iRhythm’s gross margin improved by 410 basis points to 70.0% due to operational efficiencies and a higher volume of patients served. Analysts from Citi and BTIG also raised their price targets, citing strong revenue growth and broad-based strength across channels and products.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.